Abstract：
UNASSIGNED: Sarcoidosis is a chronic granulomatous of unknown etiology that mostly affects lungs with an heterogenous clinical presentation and prognosis. Therefore, therapeutic management of the disease is challenging. The goals of treatment are to prevent or to minimize organ damage, to relieve symptoms, and to improve the patient\'s quality of life.
UNASSIGNED: The present review covers current pharmacotherapy options for pulmonary sarcoidosis. Corticosteroids are still the first-line treatment option, however, for those patients with prolonged expectation of treatment, undesirable side effects and refractory disease, immunosuppressive drugs are preferred options. Biological drugs are promising third line therapies. Recent evidence shows that antifibrotic agents, such as nintedanib, have a role in fibrotic lung disease, as well as efzofitimob, which has shown promising results in controlling inflammatory lung disease.
UNASSIGNED: Sarcoidosis treatment is evolving as new molecules are available. The number of studies of therapies for pulmonary sarcoidosis has increased in recent years, however, the information available is still limited and there is no consensus on how to monitor the activity of the disease.
UNASSIGNED: The present review covers current pharmacotherapy options for pulmonary sarcoidosis. Corticosteroids are still the first-line treatment option, however, for those patients with prolonged expectation of treatment, undesirable side effects and refractory disease, immunosuppressive drugs are preferred options. Biological drugs are promising third line therapies. Recent evidence shows that antifibrotic agents, such as nintedanib, have a role in fibrotic lung disease, as well as efzofitimob, which has shown promising results in controlling inflammatory lung disease.
UNASSIGNED: Sarcoidosis treatment is evolving as new molecules are available. The number of studies of therapies for pulmonary sarcoidosis has increased in recent years, however, the information available is still limited and there is no consensus on how to monitor the activity of the disease.
摘要：
■结节病是一种病因不明的慢性肉芽肿，主要影响肺部，临床表现和预后均不均匀。因此,该疾病的治疗管理具有挑战性。治疗的目标是预防或尽量减少器官损伤，为了缓解症状，提高患者的生活质量。
■本综述涵盖了目前肺结节病的药物治疗选择。皮质类固醇仍然是一线治疗选择,然而,对于那些长期期望治疗的患者，不良副作用和难治性疾病，免疫抑制药物是首选。生物药物是有前途的三线疗法。最近的证据表明，抗纤维化药物，比如Nintedanib,在纤维化肺病中起作用，以及efzofitimob，在控制炎症性肺病方面显示出有希望的结果。
■结节病治疗随着新分子的出现而不断发展。近年来，对肺结节病治疗的研究数量有所增加，然而,现有的信息仍然有限，并且在如何监测疾病的活动方面没有达成共识。
■本综述涵盖了目前肺结节病的药物治疗选择。皮质类固醇仍然是一线治疗选择,然而,对于那些长期期望治疗的患者，不良副作用和难治性疾病，免疫抑制药物是首选。生物药物是有前途的三线疗法。最近的证据表明，抗纤维化药物，比如Nintedanib,在纤维化肺病中起作用，以及efzofitimob，在控制炎症性肺病方面显示出有希望的结果。
■结节病治疗随着新分子的出现而不断发展。近年来，对肺结节病治疗的研究数量有所增加，然而,现有的信息仍然有限，并且在如何监测疾病的活动方面没有达成共识。
